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Abstract
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is now the factor behind the development of liver 
cirrhosis, liver cell failure, and liver transplantation in many cases. However, its relation to atrial fibrillation (AF) could 
not be cleared up. 
AIM: The purpose of the study was to evaluate prevalence of AF in the setting of NAFLD; the association between 
them, and to evaluate risk factors of AF in this category of patients.
METHODS: This cross-sectional study was performed on 400 patients between January 2018 and June 2019. These 
patients were analyzed for the presence of NAFLD and presence of persistent or chronic AF.
RESULTS: There were 138 patients with NAFLD, and 20 patients with persistent or permanent AF. Factors associated 
with AF were old age, male gender, and high values of aspartate aminotransferase, alanine-aminotransferase, 
γ-glutamyltranspeptidase, and serum uric acid. The participants with AF had a significantly greater prevalence of 
NAFLD than those without AF.
CONCLUSION: Incidence and prevalence of atrial fibrillation in NAFLD patients were high. Severity of liver disease 
was an important predictor of new-onset atrial fibrillation.
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Introduction
Liver disease has an impact on autonomic 
nervous system through affecting circulating 
inflammatory peptides. This effect creates a 
proarrhythmic status [1], [2], [3], [4]. Autonomic 
dysfunction and inflammation seems to have a role in 
the development of atrial fibrillation (AF) [5].
There are few studies about AF in liver 
diseases, and these studied did not assess the severity 
of liver disease [6], [7], [8].
The prevalence of nonalcoholic fatty liver 
disease (NAFLD) could not be known accurately because 
of its variability in different people including age, gender, 
ethnicity, and various concomitant diseases. In addition, 
the different methods of NAFLD detection, including liver 
enzyme, imaging analysis (i.e., ultrasound or magnetic 
resonance imaging), and histological analysis make 
accurate detection of the prevalence too hard. Younossi 
et al., 20l8 [8] performed a meta-analysis, showing that 
30–35% of adult North Americans had NAFLD (as detected 
by ultrasonography), 20–30% [9], [10] of Europeans and 
the Middle Easterners had NAFLD, and the prevalence 
of NALFD among the Chinese and Japanese was from 
15 to 30% and 20 to 30%, respectively [11], [12]. For 
Indian subcontinent populations, the prevalence was 
from 16% to 32% [13].
It is clear that the prevalence of NAFLD is much 
higher in special groups of populations (i.e., patients with 
dyslipidemia T2DM, obesity, or hypertension) [3], [14], 
NASH prevalence was reported to be from 30% to 70% 
in Type II DM population-based studies and from 45% 
to 75% in large hospital-based studies [14].
AF is the most common supraventricular 
arrhythmia seen in clinical practice in spite of improvement 
in management of cardiovascular disorders [15].
Käräjämäki et al., 2016 [16] detected 
independent association between NAFLD and high 
incidence of AF. This study aimed to evaluate prevalence 
of AF in the setting of NAFLD; the association between 
them and to evaluate risk factors of AF in this category 
of patients.
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Methods
This cross-sectional study included 
400 patients who were received in outpatient clinics 
in the Cardiology and Hepatology Departments in a 
major university hospital in the period from January 
2018 until June 2019 after taking consent from every 
one. The study protocol was reviewed and approved 
by the Ethics Committee (at Tanta Faculty of Medicine). 
All patients were informed and agreed to share in the 
study. Patients whose alcoholic history was unknown 
or known to be excessive alcoholic were excluded from 
the study.
Clinical examinations, including anthropometric 
and laboratory measurements, were performed. Weight 
and height were measured with basic clothing after 
shoes removal. Body mass index (BMI) was calculated 
(Wt [kg]/height2 [m2]). Blood pressure was measured by 
sphygmomanometer in a sitting position. Fasting plasma 
glucose (FPG), triglycerides (TG), total cholesterol (TC), 
high-density lipoprotein (HDL), low-density lipoprotein 
(LDL), alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), γ-glutamyltranspeptidase 
(GGT), serum uric acid, and albumin were measured 
using antecubital vein fasting blood samples. All values 
were measured using an Olympus AU640 autoanalyzer 
(Olympus, Kobe, Japan) and standard methods.
Diagnosis of NAFLD was based according to 
abdominal ultrasonography performed by well-trained 
operators who were blind to the laboratory and clinical 
data, and after excluding other etiology. The apparatus 
used was a Toshiba Nemio 20 sonography machine 
with a 3.5-MHz probe (Toshiba, Tokyo, Japan) [15].
Diagnostic criteria of fatty liver included: 
(1) Increased liver brightness; (2) diffuse 
hyperechogenicity of the liver compared to the 
kidneys; (3) deep attenuation of hepatic echo; and 
(4) intrahepatic vessel borders and diaphragm [16]. 
This study used ultrasonography also for evaluation of 
intra-abdominal organs (liver, spleen gallbladder, and 
pancreas).
AF was diagnosed using a 12-lead 
electrocardiogram (ECG) showing irregularly irregular 
ventricular rate and absent discrete P waves.
Statistical analysis
The collected data were tabulated and 
statistically analyzed using Prism 5 software statistical 
computer package version 5. Range, mean, standard 
deviation, number, and percent were calculated. Chi-
square and Fisher exact test were used as a test of 
significance. Continuous variables between the two 
groups were compared with the t-test. p < 0.05 was 
considered significance.
Results
Clinical characteristics of the included patients: 
Of the 400 participants included in this study, 138 met 
the diagnostic criteria for NAFLD (34.5%, 98 males and 
40 females). Of the entire sample, 20 participants (5.0%, 
16 males and 4 females) had persistent or permanent 
AF. The clinical characteristics of patients are shown in 
Table 1. Patients with AF were older, more likely to be 
male, and had significantly higher values of AST, ALT, 
GGT, serum uric acid. BMI, blood pressure, lipid profile, 
albumin, and FPG did not significantly differ between 
the two groups. As shown in Table 1, the participants 
Table 1: Baseline clinical, demographic, and characteristics of 
studied patients stratified by AF status
Characteristic All pts (n=400) Pts without AF 
(n=380)
Pts with AF 
(n=20)
t value p value*
Age (years): 
Mean ± SD
60.5 ± 9.2 59.2 ± 8.0 64.6 ± 9.5 2.015 0.0093
Gender, No. 
(M/F)
291/109 276/104 16/4 2.08 0.08
BMI (kg/m) 24.90 ± 2.70 23.60 ± 3.00 23.70 ± 2.80 0.145 0.88
Systolic BP 135.10 ± 15.00 134.30 ± 15.10 136.10 ± 14.60 0.520 0.60
Diastolic BP 73.40 ± 11.60 72.60 ± 11.80 73.40 ± 12.10 0.292 0.768
FPG (mg/dl) 108.50 ± 12.30 110.40 ±  11.90 105.8 ± 12.70 1.67 0.09
Total chol. (mg) 176.50 ± 19.80 175.40 ± 19.60 165.50 ± 20.70 1.28 0.198
HDL (mg/dl 40.96 ± 4.58 40.26 ± 4.64 38.64 ± 3.70 1.53 0.125
LDL (mg/dl) 131.65 ± 19.50 130.60 ± 19.20 128.50 ± 18.90 0.477 0.633
TG (mg/dl) 164.50 ± 22.10 162.70 ± 21.0 157.30 ± 19.80 1.124 0.260
AST (U/L) 32.10 ± 3.72 31.80 ± 3.70 33.90 ± 3.91 2.40 0.014
ALT (U/L) 24.82 ± 3.94 24.50 ± 3.90 26.30 ± 4.10 2.01 0.045
γ-GTP (U/L) 22.49 ± 3.60 22.41 ± 3.50 24.20 ± 4.00 2.20 0.0275
Albumin(g/L) 44.83 ± 2.80 44.54 ± 2.70 45.28 ± 2.90 1.190 0.234
Serum UA 
(mg/dL)
5.23 ± 1.64 5.10 ± 1.60 5.90 ± 2.85 2.33 0.020
NAFLD (%) 33.4 33.2 44.4
AST: Aspartate aminotransferase, ALT: Alanine aminotransferase, GTP: Glutamyltranspeptidase, 
LDL: Low-density lipoprotein, HDL: High-density lipoprotein, FPG: Fasting plasma glucose, 
TG: Triglycerides, BMI: Body mass index, M/F: Male/female, BP: Blood pressure, AF: Atrial fibrillation, 
NAFLD: Nonalcoholic fatty liver disease.
with AF had a significantly greater prevalence of NAFLD 
than those without AF. As regards NAFLD status 
(Table 2), the group of NAFLD contained more males 
and was slightly older than the group without NAFLD. 
The values for SBP, DBP, BMI, LDL, TG, AST, ALT, 
GGT, FPG, albumin, and serum UA were higher among 
the participants with NAFLD; but, they had lower values 
of HDL. Furthermore, as shown in Table 2, there was 
a marked difference in the prevalence of AF among 
participants with or without NAFLD.
Table 2: Baseline clinical, demographic, and characteristics of 
studied patients stratified by NAFLD status
Characteristic Pts without NAFLD 
(n=272)
Pts with NAFLD 
(n=138)
t value p value*
Age (years): Mean ± SD 61.20 ± 8.80 62.20 ± 8.60 1.09 0.273
Gender, No. (M/F) 170/102 98/40 1.4 0.294
BMI (kg/m) 24.00 ± 2.800 23.90 ± 2.90 0.337 0.7358
Systolic BP 133.40 ± 16.80 138.20 ± 18.30 2.82 0.005
Diastolic BP 72.70 ± 12.00 75.90 ± 11.80 2.56 0.0106
FPG (mg/dl) 112.30 ± 11.80 118.40 ± 13.20 4.6 0.001
Total chol. (mg) 154.30 ± 12.40 160.25 ± 11.60 1.32 0.203
HDL (mg/dl 42.20 ± 6.40 38.10 ± 4.6 6.534 0.001
LDL (mg/dl) 120.40 ± 17.80 126.20 ± 19.30 3.03 0.0026
TG (mg/dl) 150.20 ± 22.80 170.30 ± 26.8 2.30 0.025
AST (U/L) 28.60 ± 4.60 32.10 ± 5.8 6.60 0.0013
ALT (U/L) 24.80 ± 3.40 30.20 ± 3.80 4.58 0.001
γ-GTP (U/L) 21.400 ± 2.800 24.60 ± 4.10 9.20 0.001
Albumin(g/L) 44.500 ± 2.900 46.20 ± 2.60 1.41 0.150
Serum UA (mg/dL) 5.00 ± 2.100 5.6 ±  3.00 2.23 0.019
AF (%) 2.1 3.8
AST: Aspartate aminotransferase, AST: Aspartate aminotransferase, ALT: Alanine aminotransferase, 
GTP: Glutamyltranspeptidase, LDL: Low-density lipoprotein, HDL: High-density lipoprotein, FPG: Fasting 
plasma glucose, TG: Triglycerides, BMI: Body mass index, M/F: Male/female, BP: Blood pressure, 
AF: Atrial fibrillation.
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The association between AF and NAFLD 
remained statistically significant even after adjustment for 
age and gender. Further adjustment for SBP, FPG, GGT, 
HDL, and TG did not remarkably change the study group’s 
status. Age and GGT were independent predictors of AF.
AST and ALT were calculated according to 
normal values up to 45 U/L. GGT was calculated with the 
upper limit 50 U/L for males and 32 U/L for females. There 
was an increasing trend of the prevalence rate of AF as 
serum liver enzyme increased. The prevalence rates of 
AF in normal and elevated serum AST groups were 2.1% 
and 9.8% (p < 0.001). The rates in normal and elevated 
serum ALT groups were 2.0% and 8.2% (p = 0.003). 
Meanwhile, the rates in GGT groups were 1.7% and 7.8% 
with significant result as well (p < 0.001). These results 
showed that participants with higher serum liver enzyme 
are more likely to develop AF than those with lower one.
Figure 1: Prevalence of atrial fibrillation in patients stratified by normal 
or elevated serum liver enzyme concentration
As regards the relationship between NAFLD 
and AF, participants were classified into three groups: 
Group without NAFLD, group with NAFLD and normal 
AST/ALT/GGT, and group with NAFLD and elevated 
AST/ALT/GGT. AF was significantly higher among 
patients with elevated liver enzymes; also, in those with 
hepatic steatosis, irrespective of liver enzymes. However, 
the presence of AF among those without hepatic steatosis 
on ultrasound was not significant (Figures 1 and 2).
Discussion
Till now, multiple similar risk factors can 
lead to both AF and NAFLD. As a result, there were 
many studies about the association between AF 
and NAFLD [17], [18], [19], [20], [21]. However, they 
were limited. A study made by Targher et al. [20] was 
restricted on subjects with type II diabetes mellitus 
and the OPERA study focused on middle-aged 
patients [16].
AF is prevalent in patients with liver disease. 
Furthermore, incidence of AF is proportional to the 
severity of liver disease, which is independently 
associated with new-onset AF, in spite of adjustment 
of other AF risk factors. This finding may explain 
additional mechanistic insight into the pathogenesis of 
AF, which shares the underlying link of inflammation 
and autonomic dysfunction, known to play a role 
in development of AF. Both cardiologists and 
hepatologists consider AF screening in patients with 
liver disease [21], [22], [23].
Our study revealed the association between 
NAFLD and AF. The serum transaminase levels were 
significantly associated with high risk of AF. It is not 
known whether the association between them is 
causative relationships or these two diseases share 
common pathophysiologic mechanisms. As it is 
reasonable to deduce that there may be a causal link 
between them because NAFLD is known to be a risk 
factor for many cardiovascular diseases.
Our finding could be explained by the following: 
First, liver transaminases may link NAFLD and AF 
which was in agreement with The Framingham Heart 
Study which detected the independent relationship 
between liver transaminase concentrations and the risk 
of new-onset AF in the general adult population [24]. 
Targher et al.’s [18] study detected that GGT was the 
only liver enzyme significantly associated with the 
prevalence of AF in Type II diabetes patients [18]. 
A similar result was found in our studied patients. 
GGT is also a systemic marker of NAFLD so that the 
development of the two diseases may be parallel. 
Furthermore, it has been proven that the most specific 
marker of liver pathology (ALT) is also associated 
with an increased risk of cardiovascular-related 
mortality [25], [26], [27], [28], [29].
As regards AST, it is produced in the both 
liver and myocardium, increases in either NAFLD 
or AF patients, or in patients with both conditions. 
This is similar to our results. Therefore, control of 
liver transaminase concentrations may have a role in 
reduction of the mortality in patients with AF.
Second, NAFLD leads to accumulation of 
lipids in the liver, impaired lipoprotein metabolism, 
increased oxidative stress, and release of inflammatory 
factors [30], which are important risk factors for 
Figure  2:  Prevalence  of  atrial  fibrillation  in  patients  stratified  by 
nonalcoholic fatty liver disease status on ultrasound combined 
with normal or elevated serum aspartate aminotransferase/alanine 
aminotransferase/γ-glutamyltranspeptidase concentration
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AF [32], [33], [34]. Furthermore, it was reported that AF 
could trigger inflammatory environment [33], creating a 
vicious cycle.
Persistent low levels of LDL and HDL cause 
further lipoprotein consumption [31]. These conclusions 
were consistent with our results where HDL cholesterol, 
LDL cholesterol, and TG were all lower in group with AF 
than in the group without AF.
Third, since NAFLD carries 
multiple cardiovascular complications, it may induce 
AF direct through several mechanisms including 
left ventricular diastolic dysfunction [35], and 
alteration of atrial conduction properties [36]. Fat 
does not accumulate only in the liver tissue but also 
in other organs and viscera including cardiac tissue 
(myocardium, pericardium, and atrial septum) so that 
the diastolic function of the atria or the ventricle, and 
electrical activity may be affected [36], [37].
Finally, many studies have reported that 
NAFLD is an independent risk factor for autonomic 
dysfunction [38], [39], [40] which has a role in 
development of AF [40], [41].
There were some limitations to our study. First, 
NAFLD was not diagnosed histologically but though 
ultrasound which was non-invasive and cost-effective. 
Second, the sample was small. Third, AF was diagnosed 
according to resting ECG without 24 h dynamic ECG 
which was more precise but more difficult. Fourth, the 
cross-sectional nature of our study did not enable us to 
know the most recent mean levels of some lab results 
of every patient. As formal cohort studies have shown, 
NAFLD is associated with an increased risk of prevalent 
AF [18], [19], [42].
Conclusion
NAFLD is an independent risk factor for 
AF mainly with the progression of liver disease. 
NAFLD patients should be examined for arrhythmia 
symptoms, and evaluated ECGs and ambulatory 
monitors. Future studies are needed to evaluate risks 
and benefits of anticoagulation in the setting of liver 
disease.
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